From Nasdaq: 2025-06-18 21:33:00

The U.S. FDA has approved Incyte’s Monjuvi for adult patients with relapsed or refractory follicular lymphoma, in combination with rituximab and lenalidomide. This is the second approved indication for Monjuvi in the U.S. Patients in a Phase 3 trial showed improved progression-free survival with Monjuvi. In July 2020, Monjuvi in combination with lenalidomide was approved for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. Tafasitamab is also being studied in a pivotal trial for first-line DLBCL. For more health news, visit rttnews.com.



Read more at Nasdaq: Incyte : FDA Approves Monjuvi Combination For R/R Follicular Lymphoma Treatment